S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier
Servier
AstraZeneca
Myeloid Therapeutics
Amgen
DualityBio Inc.
Boehringer Ingelheim
NextCure, Inc.
Tanabe Pharma America, Inc.
Bayer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bolt Biotherapeutics, Inc.
Institut Bergonié
Yuhan Corporation
Bristol-Myers Squibb
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Instituto do Cancer do Estado de São Paulo
Evopoint Biosciences Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Vincerx Pharma, Inc.
Taiho Pharmaceutical Co., Ltd.
Eli Lilly and Company
Universitair Ziekenhuis Brussel
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Cantargia AB
Institut Bergonié
Ambrx, Inc.
Kyunghee University Medical Center
Herlev and Gentofte Hospital
AstraZeneca
Azienda Ospedaliero-Universitaria di Parma